Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cyduct Diagnostics's revenue for the
three
months ended in . 20 was $0.00 Mil.
Cyduct Diagnostics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in . 20.
Cyduct Diagnostics's Revenue per Share for the
three
months ended in . 20 was $0.00.
Cyduct Diagnostics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in . 20.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cyduct Diagnostics Revenue Related Terms
Cyduct Diagnostics Revenue Historical Data
* Premium members only.
The historical data trend for Cyduct Diagnostics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyduct Diagnostics Revenue Chart
Cyduct Diagnostics Annual Data
Trend
Revenue
Cyduct Diagnostics Quarterly Data
Revenue
CYDX vs SECI, QTXB, ASNB: Revenue Comparison
For the Medical Devices subindustry, Cyduct Diagnostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyduct Diagnostics Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's Revenue distribution charts can be found below:
* The bar in red indicates where Cyduct Diagnostics's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Cyduct Diagnostics (CYDX) has a Revenue of $ Mil as of . 20. Revenue is the total amount a company generates as sales through its operations. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Revenue too high?
Cyduct Diagnostics' current Revenue is $ Mil.
How does Cyduct Diagnostics' Revenue compare to SECI and QTXB?
Cyduct Diagnostics' Revenue of $ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Revenue is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Revenue of $ Mil. The current Revenue is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Revenue is $ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYDX has been successfully added to your 
